166 related articles for article (PubMed ID: 27253231)
1. A Randomized Comparative Study of 24- and 6-Hour Infusion of Nafamostat Mesilate for the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective Randomized Comparison Trial.
Kim SJ; Kang DH; Kim HW; Choi CW; Park SB; Song BJ; Nam HS
Pancreas; 2016 Sep; 45(8):1179-83. PubMed ID: 27253231
[TBL] [Abstract][Full Text] [Related]
2. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?
Park KT; Kang DH; Choi CW; Cho M; Park SB; Kim HW; Kim DU; Chung CW; Yoon KT
Pancreas; 2011 Nov; 40(8):1215-9. PubMed ID: 21775918
[TBL] [Abstract][Full Text] [Related]
3. The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis.
Kim JS; Lee SH; Park N; Huh G; Chun JW; Choi JH; Cho IR; Paik WH; Ryu JK; Kim YT
BMC Gastroenterol; 2022 May; 22(1):271. PubMed ID: 35641898
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial for efficacy of nafamostat mesilate in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Ohuchida J; Chijiiwa K; Imamura N; Nagano M; Hiyoshi M
Pancreas; 2015 Apr; 44(3):415-21. PubMed ID: 25479585
[TBL] [Abstract][Full Text] [Related]
5. Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: a prospective, randomized trial.
Park JY; Jeon TJ; Hwang MW; Sinn DH; Oh TH; Shin WC; Choi WC
Pancreatology; 2014; 14(4):263-7. PubMed ID: 25062874
[TBL] [Abstract][Full Text] [Related]
6. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis.
Choi CW; Kang DH; Kim GH; Eum JS; Lee SM; Song GA; Kim DU; Kim ID; Cho M
Gastrointest Endosc; 2009 Apr; 69(4):e11-8. PubMed ID: 19327467
[TBL] [Abstract][Full Text] [Related]
7. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials.
Xie Y; Cheng Z; Deng C; Deng M; Zhang H
Medicine (Baltimore); 2023 Oct; 102(41):e35174. PubMed ID: 37832051
[TBL] [Abstract][Full Text] [Related]
8. Nafamostat mesilate for prevention of post-ERCP pancreatitis: a meta-analysis of prospective, randomized, controlled trials.
Yu G; Li S; Wan R; Wang X; Hu G
Pancreas; 2015 May; 44(4):561-9. PubMed ID: 25822153
[TBL] [Abstract][Full Text] [Related]
9. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized, double-blind, controlled trial.
Yoo KS; Huh KR; Kim YJ; Kim KO; Park CH; Hahn T; Park SH; Kim JH; Park CK; Kwon YJ; Lehman GA
Pancreas; 2011 Mar; 40(2):181-6. PubMed ID: 21206331
[TBL] [Abstract][Full Text] [Related]
10. Preventative Effect of Nafamostat Mesilate Infusion into the Main Pancreatic Duct on Post-ERCP Pancreatitis in a Porcine Model: Initial Pilot Study.
Park JS; Jeong S; Kim JM; Lee DH
J Invest Surg; 2020 Apr; 33(4):325-331. PubMed ID: 30884994
[No Abstract] [Full Text] [Related]
11. Nafamostat Mesylate is Not Effective in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis.
Matsumoto T; Okuwaki K; Imaizumi H; Kida M; Iwai T; Yamauchi H; Kaneko T; Hasegawa R; Masutani H; Tadehara M; Adachi K; Watanabe M; Kurosu T; Tamaki A; Kikuchi H; Ohno T; Koizumi W
Dig Dis Sci; 2021 Dec; 66(12):4475-4484. PubMed ID: 33495919
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of nafamostat mesylate in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography: a systematic review and meta-analysis of randomized controlled trials.
Narumi K; Okada T; Lin Y; Kikuchi S
Sci Rep; 2023 Dec; 13(1):23012. PubMed ID: 38155200
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of gabexate mesilate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized clinical trials.
Chiu YJ; Chen SC; Kang YN; Hou SK; Chao CC; Chang CC
J Formos Med Assoc; 2021 Apr; 120(4):1090-1099. PubMed ID: 33183879
[TBL] [Abstract][Full Text] [Related]
14. Nafamostat Reduces the Incidence of post-ERCP Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Horváth IL; Kleiner D; Nagy R; Fehérvári P; Hankó B; Hegyi P; Csupor D
Clin Pharmacol Ther; 2024 Feb; 115(2):206-212. PubMed ID: 38032816
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis.
Yuhara H; Ogawa M; Kawaguchi Y; Igarashi M; Shimosegawa T; Mine T
J Gastroenterol; 2014 Mar; 49(3):388-99. PubMed ID: 23720090
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Using 4-Hour Post-Endoscopic Retrograde Cholangiopancreatography Serum Amylase and Lipase Levels.
Lee YK; Yang MJ; Kim SS; Noh CK; Cho HJ; Lim SG; Hwang JC; Yoo BM; Kim JH
J Korean Med Sci; 2017 Nov; 32(11):1814-1819. PubMed ID: 28960034
[TBL] [Abstract][Full Text] [Related]
17. [Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?].
Kwon YH; Kim JY; Lee SJ; Jang SY; Park HW; Yang HM; Jung MK; Jeon SW; Cho CM; Tak WY; Kweon YO; Kim SK
Korean J Gastroenterol; 2012 Mar; 59(3):232-8. PubMed ID: 22460572
[TBL] [Abstract][Full Text] [Related]
18. Is prophylactic somatostatin effective to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis or hyperamylasemia? A randomized, placebo-controlled pilot trial.
Wang ZK; Yang YS; Cai FC; Wang YH; Shi XL; Ding C; Li W
Chin Med J (Engl); 2013 Jul; 126(13):2403-8. PubMed ID: 23823808
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic pancreatic duct stents reduce the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients.
Sofuni A; Maguchi H; Mukai T; Kawakami H; Irisawa A; Kubota K; Okaniwa S; Kikuyama M; Kutsumi H; Hanada K; Ueki T; Itoi T
Clin Gastroenterol Hepatol; 2011 Oct; 9(10):851-8; quiz e110. PubMed ID: 21749851
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib Oral Administration for Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Randomized Prospective Trial.
Kato K; Shiba M; Kakiya Y; Maruyama H; Ominami M; Fukunaga S; Sugimori S; Nagami Y; Watanabe T; Tominaga K; Fujiwara Y
Pancreas; 2017 Aug; 46(7):880-886. PubMed ID: 28697127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
